Navigation Links
Isolagen to Present at the JMP Securities Healthcare Focus Conference
Date:10/3/2008

EXTON, Pa., Oct. 3 /PRNewswire-FirstCall/ -- Isolagen, Inc. (Amex: ILE) announced today that Declan Daly, Chief Executive Officer, will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 3:30 p.m. (EST) at Le Parker Meridien hotel in New York, New York.

The presentation will be webcast live and can be accessed on the Isolagen website, http://www.isolagen.com, on the investors page. A replay will be available approximately three hours after the presentation and will be archived on the company's website for 90 days.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in Item 1A. "Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
2. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
3. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
5. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. ViroPharma to Present at Three October Healthcare Conferences
10. BioCryst to Present at the JMP Healthcare Focus Conference
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... and GERMANTOWN, Maryland , February ... Prime Standard: QIA) today announced the introduction of more ... expression profiling, expanding QIAGEN,s portfolio of Sample to Insight ... to select from over 20,000 human genes and lncRNA ... genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which has created ... pursue the highest level of accuracy and quality with the addition of two ... AR5 Refractometer. Accurate, reliable and tough enough for the most demanding applications, ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
Breaking Biology News(10 mins):